PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE FENTON PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOTAB DEBRITONE DEBRITONE BELLABITONE BELLABITONE BELLABITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE BELLABARBITONE BELLADONNA PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE PHENOBARBITONE EROPYRIN EROPYRIN ASTHYLINE PHENOTONE PHENOBARBITONE PHENOBARBITONE PHENOBAR PHENO PHENOLA PHENODAN BUTONE GRAYFIN GRAYFIN PHENOMED PHENOMED PHENOMED PHENOSUN PHENFIT PHENOBAR PHENOBAR PHENOBARB PHENOSAL LENTON

Dose: 50 to 200 mg
Single Dose: 120 (125)
Frequency: 6 hourly
Route: IV,IM
Instructions:

Dose: 3.1 mg/kg
Single Dose: 3.1 (3.1)
Frequency: 24 hourly
Route: Oral
Instructions: -

Dose: 3.1 mg/kg
Single Dose: 3.1 (3.1)
Frequency: 24 hourly
Route: Oral
Instructions: -

Phenobarbitone also known as Ethophenylbarbituric Acid, Ethophenylbarbituric Acid. . It is of Synthetic origin and belongs to Barbiturate. It belongs to Chloride Channel opener (Gaba operated) pharmacological group on the basis of mechanism of action. The Molecular Weight of Phenobarbitone is 232.20. It is weakly alkaline drug, 3.95% solution of the drug is isotonic and Its pKa is 7.2.

Phenobarbitone is contraindicated in conditions like Porphyrias,Hepatic disease.

The severe or irreversible adverse effects of Phenobarbitone, which give rise to further complications include Ataxia, Confusion, Aggression, Irritability, Nystagmus, Mental disturbances.Phenobarbitone produces potentially life-threatening effects which include Agranulocytosis, Aplastic Anemia, Exfoliative dermatitis, Hepatitis. which are responsible for the discontinuation of Phenobarbitone therapy.The signs and symptoms that are produced after the acute overdosage of Phenobarbitone include Coma and death, Sedation, Stupor.The symptomatic adverse reactions produced by Phenobarbitone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Skin rashes, Erythema, Morbiliform.

Phenobarbitone is primarily indicated in conditions like Benign febrile convulsions of infancy, Epilepsy, Seizures, Short-term treatment of severe congestive heart failure, Status epilepticus.

Phenobarbitone is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAbacavirPhenobarbital reduces plasma concentration of abacavir.AlcoholAlfacalcidolit reduces hydroxilation of alfacalcidolAmoxapineAmoxapine antagonises antconvulsant effect of phenobarbitone; convuksive threshold lowered. Metabolism of amoxapine possibly accelerated; reduced plasma concentration. Bupropion (HCl)CalcifediolCarbamazepinePhenobarbitone may decreases Carbamazepine levels. The mechanism may be related to induction of CYP450 hepatic metabolism of Carbamazepine.CarmustineChloramphenicolPhenobarbitone causes subtherapeutic concentration of chloramphenicol.ChloramphenicolChlorpropamideClonazepamCorticotropinCyclosporin ADesogestrelDexamethasonephenobarbitone decrease plasma half life and bioavailibility of dexamethasone by 50%Dexamphetamine (Sulphate)DextropropoxypheneDiazepamBarbiturates (e.g. Phenobarbitone) potentiate the action of Diazepam and should not be given concurrentlyDigitoxinDigitoxinDi-IodohydroxyquinolineDiltiazem (HCl)Dimemorfan PhosphateDiphenhydramineDipyroneDisopyramideDoxycyclineDoxycyclineDydrogesteroneEphedrineEstazolamEstradiol (Valerate)EthinyloestradiolEthosuximideEthynodiol (Diacetate)FlunisolideFosphenytoinGallopamilGestodeneGriseofulvinGriseofulvinHydrocortisoneIndinavir (Sulphate)Influenza VaccineIopanoic AcidIotroxate (Meglumine)ItraconazoleLamotrigineLevonorgestrelLynoestrenolMegestrol (Acetate)MephenytoinPhenobarbital may interact with Mephenytoin. It can either increase or decrease the effect of Mephenytoin. MethylprednisoloneBarbiturates (e.g. Phenobarbitone ) can increase metabolism of methyl prednisoloneNicoumaloneNorgestimateNortriptyline (HCl)PemolineEffects may be additive. Use caution when pemoline is used with other CNS acting medicationsPethidine (HCl)PhenindionePhenylbutazone Phenytoin (Na)Phenytoin (Na)PioglitazonePrajmalium Bitartaratephenobarbitone increases hepatic metabolism of prajmalium bitartarate.ProgesteronePropoxyphenePyridoxinePyridoxineQuinidineRepaglinidePhenobarbitone may decrease the levels/effects of repaglinide.RitonavirSecnidazoleSertindoleSertindole has the potential of causing drowsiness, thus in combination Phenobarbitone sedation may result. Sodium ValproateStilboestrolTacrolimusTelithromycinPhenobarbitone is likely to result in subtherapeutic levels of telithromycin and loss of effect.Thiamine HCl (Vitamin B1)Barbiturates may lower thiamin levels in the body by decreasing absorption and increasing excretion or metabolism.Tiagabine (HCl)Tocainide (HCl)Verapamil (HCl)Vitamin KWarfarin (Na)Phenobarbitone may increase the metabolism, via CYP isoenzymes, of Warfarin. MajorDelayedMonitor for decreased therapeutic effects of Warfarin if Phenobarbitone is initiated/dose increased (anticoagulant dosage increases of 30% to 60% may be needed based on monitored PT), or increased effects if Phenobarbitone is discontinued/dose decreased. An increased frequency of PT monitoring should be considered for the period immediately following Phenobarbitone initiation/dosage changes. Zolpidem (Tartrate) These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store Below 40°C. Do not Freeze. Tab Store in a well closed container, Below 40°C.

Phenobarbitone should be used with extreme caution in case of severe liver function, pulmonary or cardiac disease, shock or uremia. Administered with caution to patients with borderline hypoadrenal function. During prolong therapy, perform periodic lab.evaluation of organ system, including renal (kidney) and hepatic (liver) system. It should be used with caution (if contains tartrazine) in patients with aspirin hypersensitivity, because may produced allergic reactions (including bronchial asthma).